Background/Aims: Visceral larva migrans, caused by Toxocara canis and Toxocara cati, has emerged as a significant cause of eosinophilic liver abscess (ELA). Differentiation of ELA associated with toxocariasis (ELA-T) from metastasis or primary liver malignancy is sometimes difficult. However, the role of albendazole treatment remains uncertain in this condition. The aim of this study was to evaluate whether albendazole can enhance the radiologic resolution of ELA-T. Methods: We retrospectively reviewed the medical records of the patients diagnosed with ELA-T at our institution between January 2008 and December 2011. ELA-T was diagnosed based on the imaging findings on computed tomography or magnetic resonance imaging and the presence of positive serum IgG antibody for Toxocara canis. Among a total of 163 patients, 32 patients received albendazole (albendazole group) and 131 did not (control group). Baseline characteristics and fate of liver nodules were compared between the two groups. Results: Baseline characteristics (age, sex, number and maximal size of lesions, eosinophil count) were similar between the two groups. Median duration for achieving radiologic resolution in the albendazole group was significantly shorter than in the control group (207 days [range 186-228] vs. 302 days [range 224-380], p=0.023). In Cox regression analysis of the cumulative rates of radiologic resolution, the hazard ratio for albendazole treatment was 1.99 (95% confidence interval, 1.22-3.23). Conclusions: Radiologic resolution of ELA-T can be accelerated with albendazole treatment. Hence, inconvenience associated with long-term follow-up and unnecessary worries among patients can be eliminated with albendazole treatment. (Korean J Gastroenterol 2015;65:222-228) 
INTRODUCTION
Eosinophilic liver abscess (ELA) is a focal eosinophilic infiltration and necrosis of the liver. It can be caused by para-sitic infection, allergic diseases, drugs and hypereosinophilic syndrome involving liver. In addition, it might be rarely associated with malignancy, primary biliary cirrhosis, primary sclerosing cholangitis, and eosinophilic gastroenteritis. 1 is more common in South Korea than in Western countries, and its characteristic clinical findings have been investigated by many authors. [1] [2] [3] [4] [5] [6] [7] In particular, toxocariasis, caused by
Toxocara canis, has emerged as a significant cause of ELA in Korea. 5, 8 Toxocariasis was originally known to be a disease affecting children. However, a habit of eating uncooked cow liver or meat has led to an increase in the prevalence of ELA associated with toxocariasis (ELA-T) among adults of this country. [5] [6] [7] [8] Only a few cases of ELA-T have been reported in Western countries. [9] [10] [11] [12] ELA-T is usually asymptomatic. 8 However, abdominal pain, fever, and fatigue can be observed in patients with high disease burden. 8 Peripheral eosinophilia is a common laboratory finding. Due to its high specificity (90-95%) and sensitivity (80%), enzyme-linked immunosorbent assay (ELISA) for specific IgG antibodies against the antigen secreted by larva is widely used for making the serologic diagnosis of toxocariasis. 13 Several studies have suggested that imaging findings of ELA-T usually consist of small (＜2 cm), multiple, and oval or trapezoid nodules with ill-defined and fuzzy margins. 4, 5, 8 However, differentiation of ELA-T from metastasis or primary liver malignancy is not always easy in actual clinical practice.
Multiple ELA-T lesions can be confused with liver metastasis, 14 especially in patients with malignancy, while single ELA-T lesions can mimic primary liver cancer such as cholangiocarcinoma or hepatocellular carcinoma. 7, [15] [16] [17] Although percutaneous biopsy or surgery can be performed to confirm the diagnosis of ELA-T in certain circumstances, [14] [15] [16] [17] [18] [19] follow-up with or without treatment is another strategy in a considerable number of patients with suspected ELA-T.
A 5-day to 7-day course of albendazole 800 mg/day has been recommended for toxocariasis in previous studies. 13, 20 However, some studies have suggested that medication is not needed for patients without symptoms since toxocariasis is a self-limiting disease. 21, 22 If albendazole treatment can promote radiologic resolution in patients with ELA-T, it can relieve unnecessary worries among patients and avoid the inconvenience of prolonged follow-up with imaging studies.
However, the role of albendazole treatment remains uncertain in these patients.
Hence, we conducted this study to elucidate whether albendazole treatment can enhance the radiologic resolution of ELA-T lesions in patients.
SUBJECTS AND METHODS

Patients
We retrospectively reviewed the medical records of pa- Radiologic resolution was defined as complete disappearance of lesions on imaging studies (Fig. 2 ).
Statistical analyses
Differences in the baseline characteristics of the two groups were evaluated using Mann-Whitney test and Fisher's exact test as indicated. The Kaplan-Meier method was used for assessing the cumulative rates of radiologic resolution and the differences were calculated using the log-rank test. Values are presented as n (%) or mean±SD. 
Clinical outcomes according to albendazole treatment
During the median follow-up period of 6.9 months (range, 1-37.3 months), 115 patients (70.6%) showed radiologic resolution. In Kaplan-Meier analysis, the median duration for achieving radiologic resolution was 207 days (range, 186-228 days) in the albendazole group, which was significantly shorter than 302 days in the control group (range, 224-380 days; p=0.023) (Fig. 4) . In Cox regression analysis of cumulative rates of radiologic resolution, the hazard ratio for alben- 1, 5, 7 While biopsy through a percutaneous approach or surgery may be performed to confirm the diagnosis in cases of difficult characterization of the lesion, ELA-T is usually diagnosed based on a combination of characteristic imaging findings and positive toxocariasis ELISA results. 5 In this study, the diagnosis of ELA was made based on histological findings in only 10 patients, and without biopsy in 153 patients. Previous studies have reported a wide range of biopsy rates (13-80%),
according to the study design. 2, 3, 5, 7 In addition, the presence of eosinophilia supports the diagnosis of ELA. In our study, among 154 patients whose initial eosinophil count was available, 121 patients (78.6%) showed eosinophilia. Eosinophilia was reported in 57-100% of patients with ELA in previous studies. [2] [3] [4] 7 Because it is known to be a self-limiting disease, there are no established indications for treatment of human toxocariasis. 23 Treatment of ELA-T depends on the severity of the patient's symptoms and the clinician's decision. Some authors agree that treatment is needed when patients' symptoms are severe. 13, 23, 24 In cases of visceral larva migrans with no or mild symptoms, it remains uncertain whether treatment is necessary. Regular imaging follow-up until resolution without histologic confirmation is commonly performed in most patients with ELA-T. If treatment with anti-helminthic drugs reduces the duration for achieving radiologic resolution, unnecessary concern of the patients and medical costs for repeated tests can be alleviated. We showed that al- Our study has a few limitations as a retrospective study.
Although baseline characteristics were comparable between the albendazole group and control group, possible bias related to physicians' preference for treatment and variable follow-up policy cannot be excluded. No consistent policy was noted with regard to deciding whether or not to treat in patients diagnosed as ELA-T without biopsy, although none of the biopsy-confirmed cases were treated. Follow-up imaging was performed at various intervals according to underlying disease, radiologic findings, or preference of physicians.
Conduct of a prospective randomized study is warranted to confirm the role of albendazole treatment in patients with ELA-T. Nevertheless, this is the first study demonstrating the benefit of albendazole treatment in patients with ELA-T, suggesting that radiologic resolution can be facilitated and the duration of follow-up can be shortened with albendazole treatment.
In conclusion, radiologic resolution can be accelerated with albendazole treatment in patients with ELA-T. Hence, treatment with albendazole would be recommended to avoid the inconvenience and undue costs associated with long-term follow up and unnecessary worries among patients with ELA-T.
